Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection - 14/04/23
Doi : 10.1016/j.jaad.2022.05.005
Soundos Youssef, MD a, Jonathan Lavian, MD b, Eunice Y. Lee, PhD a, c, Weijia Fan, MS d, Lindsey A. Bordone, MD a, ⁎ 
a Department of Dermatology, Columbia University Irving Medical Center, New York, New York
b Department of Dermatology, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York
c Medical Scientist Training Program, Columbia University, New York, New York
d Department of Biostatistics, Columbia University, New York, New York
∗Correspondence and reprint requests to: Lindsey A. Bordone, MD, Department of Dermatology, Columbia University Irving Medical Center, 161 Fort Washington Avenue, New York, NY 10032Department of DermatologyColumbia University Irving Medical Center161 Fort Washington AvenueNew YorkNY10032
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : alopecia areata, COVID-19 infection, JAK inhibitor, SARS-CoV-2, tofacitinib
| Funding sources: None. |
|
| IRB approval status: Reviewed and approved by Columbia University’s Human Research Protection Office IRB (protocol # IRB-AAAT5890). |
© 2022
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 88 - N° 5
P. 1125-1127 - mai 2023 Retour au numéro
Article précédent
- Development of a patient-reported outcome questionnaire to assess signs and symptoms of hidradenitis suppurativa: The Hidradenitis Suppurativa Symptom Diary
- Afsaneh Alavi, Sarah Baradaran, Susan D. Mathias, Hilary H. Colwell, Michael Song, Iltefat H. Hamzavi, Chenglong Han
- Increased fluconazole usage by dermatologists in the Medicare provider utilization and payment database, 2014-2019
- Julianne M. Falotico, Yu Wang, Uzma Rahman, Shari R. Lipner
Bienvenue sur EM-consulte, la référence des professionnels de santé.